Overcoming the challenges of phytochemicals in triple negative breast cancer therapy : the path forward

Show simple item record

dc.contributor.author Alaouna, Mohammed
dc.contributor.author Penny, Clement
dc.contributor.author Hull, Rodney
dc.contributor.author Molefi, Thulo
dc.contributor.author Chauke-Malinga, Nkhensani
dc.contributor.author Khanyile, Richard
dc.contributor.author Makgoka, Malose
dc.contributor.author Bida, Meshack
dc.contributor.author Dlamini, Zodwa
dc.date.accessioned 2024-09-13T13:05:09Z
dc.date.available 2024-09-13T13:05:09Z
dc.date.issued 2023-06-16
dc.description.abstract Triple negative breast cancer (TNBC) is a very aggressive subtype of breast cancer that lacks estrogen, progesterone, and HER2 receptor expression. TNBC is thought to be produced by Wnt, Notch, TGF-beta, and VEGF pathway activation, which leads to cell invasion and metastasis. To address this, the use of phytochemicals as a therapeutic option for TNBC has been researched. Plants contain natural compounds known as phytochemicals. Curcumin, resveratrol, and EGCG are phytochemicals that have been found to inhibit the pathways that cause TNBC, but their limited bioavailability and lack of clinical evidence for their use as single therapies pose challenges to the use of these phytochemical therapies. More research is required to better understand the role of phytochemicals in TNBC therapy, or to advance the development of more effective delivery mechanisms for these phytochemicals to the site where they are required. This review will discuss the promise shown by phytochemicals as a treatment option for TNBC. en_US
dc.description.department Anatomical Pathology en_US
dc.description.department Medical Microbiology en_US
dc.description.department Surgery en_US
dc.description.librarian am2024 en_US
dc.description.sdg SDG-03:Good heatlh and well-being en_US
dc.description.sponsorship The South African Medical Research Council (SAMRC) and the National Research Foundation (NRF). en_US
dc.description.uri https://www.mdpi.com/journal/plants en_US
dc.identifier.citation Alaouna, M.; Penny, C.; Hull, R.; Molefi, T.; Chauke-Malinga, N.; Khanyile, R.; Makgoka, M.; Bida, M.; Dlamini, Z. Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward. Plants 2023, 12, 2350. https://DOI.org/10.3390/plants12122350. en_US
dc.identifier.issn 2223-7747 (online)
dc.identifier.other 10.3390/plants12122350
dc.identifier.uri http://hdl.handle.net/2263/98226
dc.language.iso en en_US
dc.publisher MDPI en_US
dc.rights © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license. en_US
dc.subject Phytomedicine en_US
dc.subject Tyrosine kinase en_US
dc.subject Wnt en_US
dc.subject Epithelial to mesenchymal transition en_US
dc.subject Angiogenesis en_US
dc.subject Metastasis en_US
dc.subject Apoptosis en_US
dc.subject Triple negative breast cancer (TNBC) en_US
dc.subject Breast cancer en_US
dc.subject SDG-03: Good health and well-being en_US
dc.title Overcoming the challenges of phytochemicals in triple negative breast cancer therapy : the path forward en_US
dc.type Article en_US


Files in this item

This item appears in the following Collection(s)

Show simple item record